Showing 25 to 27 of 27 results
FDA Approves First Prescription Sleep Apnea Drug: Zepbound
The Food and Drug Administration (FDA) approved Zepbound, a drug previously approved for weight loss, as the first prescription medication to treat sleep apnea, affecting an estimated 39 million American adults.
FDA Approves First Prescription Sleep Apnea Drug: Zepbound
The Food and Drug Administration (FDA) approved Zepbound, a drug previously approved for weight loss, as the first prescription medication to treat sleep apnea, affecting an estimated 39 million American adults.
Progress
36% Bias Score
Eli Lilly Stock Rebounds After Initial Post-Election Dip
Post-election, Eli Lilly's stock initially fell 6% due to concerns over President-elect Trump's choice for Health and Human Services, but has since rebounded due to meetings between Eli Lilly's CEO and the President-elect, coupled with Elon Musk's public support for affordable weight-loss drugs, ind...
Eli Lilly Stock Rebounds After Initial Post-Election Dip
Post-election, Eli Lilly's stock initially fell 6% due to concerns over President-elect Trump's choice for Health and Human Services, but has since rebounded due to meetings between Eli Lilly's CEO and the President-elect, coupled with Elon Musk's public support for affordable weight-loss drugs, ind...
Progress
44% Bias Score
FDA Approves Zepbound for Obstructive Sleep Apnea
The FDA approved Eli Lilly's Zepbound for treating obstructive sleep apnea (OSA), expanding its use beyond obesity; clinical trials showed 43-51.5% disease resolution in patients compared to 13.6-14.9% with placebo, potentially impacting 80 million Americans with OSA.
FDA Approves Zepbound for Obstructive Sleep Apnea
The FDA approved Eli Lilly's Zepbound for treating obstructive sleep apnea (OSA), expanding its use beyond obesity; clinical trials showed 43-51.5% disease resolution in patients compared to 13.6-14.9% with placebo, potentially impacting 80 million Americans with OSA.
Progress
56% Bias Score
Showing 25 to 27 of 27 results